Acute myeloid leukemia (AML) with mutant CCAAT/enhancer binding protein α (CEBPA) accounts for 5.1–18.9% of patients with AML; a higher incidence rate is observed in patients with AML from Asia than in those from Western countries [1–7]. This evidence concerns the gene CEBPA and acute myeloid leukemia.